Fujifilm biotechnologies expands strategic partnership with argenx to include u.s. manufacturing operations

Holly springs, n.c.--(business wire)--fujifilm biotechnologies, a world-leading contract development and manufacturing organization for biologics, vaccines, and advanced therapies, today announced a significant expansion of its global partnership with argenx se, a global immunology company. as part of the expanded agreement, fujifilm biotechnologies will initiate manufacturing of argenx' drug substance for efgartigimod at the holly springs, north carolina, site in 2028. argenx is the first anno.
ARGX Ratings Summary
ARGX Quant Ranking